孤立性远端深静脉血栓形成患者的抗凝治疗:一项Meta分析
该系统评价与Meta分析纳入随机和队列研究,评估孤立性远端深静脉血栓形成(IDDVT)患者抗凝 versus 不抗凝、以及抗凝6周 versus 超过6周的临床获益。结果显示抗凝降低复发性静脉血栓栓塞和肺栓塞发生率,不增加大出血风险;超过6周抗凝较6周降低复发性静脉血栓栓塞。
要点
- IDDVT患者抗凝(治疗性或预防性)较不抗凝降低复发性静脉血栓栓塞(OR 0.50,95%CI 0.31-0.79)。
- 抗凝组肺栓塞发生率低于对照组(OR 0.48,95%CI 0.25-0.91),大出血风险未增加(OR 0.64,95%CI 0.15-2.73)。
- 抗凝超过6周较6周降低复发性静脉血栓栓塞(OR 0.39,95%CI 0.17-0.90),作者认为应优先选择超过6周的抗凝疗程。
核心结论
- 在IDDVT患者中,与不抗凝相比,抗凝(治疗性和预防性)降低复发性静脉血栓栓塞发生率和肺栓塞发生率,且不增加大出血风险。
- 抗凝超过6周应优先于较短疗程。
研究设计与样本
- 对随机对照研究和队列研究进行的Meta分析,纳入IDDVT患者,比较抗凝 versus 不抗凝以及抗凝6周 versus 超过6周。
主要发现
- 抗凝组 versus 不抗凝组复发性静脉血栓栓塞:20项研究、2936例患者,OR 0.50(95%CI 0.31-0.79)。
- 抗凝组 versus 不抗凝组大出血:OR 0.64(95%CI 0.15-2.73)。
- 抗凝组 versus 对照组肺栓塞:15项研究、1997例患者,OR 0.48(95%CI 0.25-0.91)。
- 抗凝超过6周组 versus 抗凝6周组复发性静脉血栓栓塞:4项研究、1136例患者,OR 0.39(95%CI 0.17-0.90)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Essentials The optimal management of isolated distal deep vein thrombosis (IDDVT) is undefined. This meta-analysis aimed to assess the clinical benefit of anticoagulation for IDDVT. Anticoagulation reduced the rate of pulmonary embolism without increasing major bleeding risk. Recurrent thromboembolism was less common with more than 6 weeks vs. 6 weeks of anticoagulation. SUMMARY: Background The optimal management of patients with isolated distal deep vein thrombosis (IDDVT), concerning both the need for anticoagulation and its duration, is undefined. Objectives We performed a meta-analysis of randomized and cohort studies in patients with IDDVT to assess the clinical benefit of: (i) anticoagulation versus no anticoagulation; and (ii) anticoagulant treatment for 6 weeks versus for > 6 weeks. Methods The primary outcome of this analysis was recurrent venous thromboembolism (proximal propagation, recurrence of deep vein thrombosis, and pulmonary embolism). Data were pooled and compared by the use of odds ratio (OR) and 95% confidence interval (CI). Results A reduction in the rate of recurrent venous thromboembolism was observed in patients who received anticoagulation relative to those who did not receive anticoagulation (either therapeutic or prophylactic) (20 studies, 2936 patients; OR 0.50, 95% CI 0.31-0.79), without an increase in the risk of major bleeding (OR 0.64, 95% CI 0.15-2.73). The rate of pulmonary embolism was lower in anticoagulant-treated patients than in controls (15 studies, 1997 patients; OR 0.48, 95% CI 0.25-0.91). A lower rate of recurrent venous thromboembolism was observed in patients who received > 6 weeks of anticoagulant therapy than in those who received 6 weeks of anticoagulant therapy (four studies, 1136 patients; OR 0.39, 95% CI 0.17-0.90). Conclusions In patients with IDDVT, anticoagulation (both therapeutic and prophylactic) reduces the rate of recurrent venous thromboembolism and the incidence of pulmonary embolism as compared with no anticoagulation, without an increased risk of major bleeding. Anticoagulation for > 6 weeks should be preferred over shorter durations.
引用
- Franco L, Giustozzi M, Agnelli G, et al. Anticoagulation in patients with isolated distal deep vein thrombosis: a meta-analysis. J Thromb Haemost. 2017. PMID: 28316124. doi:10.1111/jth.13677
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。